These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 25645656)
1. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis. Lerch K; Meyer AH; Stroux A; Hirt C; Keller U; Viardot A; Marks R; Schreiber S; Pezzutto A; Scholz CW Ann Hematol; 2015 Jun; 94(6):981-8. PubMed ID: 25645656 [TBL] [Abstract][Full Text] [Related]
2. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650 [TBL] [Abstract][Full Text] [Related]
3. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082 [TBL] [Abstract][Full Text] [Related]
4. Survival of patients with transformed lymphoma in the rituximab era. Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374 [TBL] [Abstract][Full Text] [Related]
5. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma. Magnano L; Balagué O; Dlouhy I; Rovira J; Karube K; Pinyol M; Rivas-Delgado A; Costa D; Martínez-Trillos A; González-Farre B; Martínez-Pozo A; Giné E; Colomer D; Delgado J; Villamor N; Campo E; López-Guillermo A Ann Oncol; 2017 Nov; 28(11):2799-2805. PubMed ID: 29045517 [TBL] [Abstract][Full Text] [Related]
6. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma. Tada K; Kim SW; Asakura Y; Hiramoto N; Yakushijin K; Kurosawa S; Tajima K; Mori S; Heike Y; Tanosaki R; Maeshima AM; Taniguchi H; Furuta K; Kagami Y; Matsuno Y; Tobinai K; Takaue Y; Fukuda T Am J Hematol; 2012 Aug; 87(8):770-5. PubMed ID: 22641292 [TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963 [TBL] [Abstract][Full Text] [Related]
8. Transformed follicular lymphoma (tFL): consolidation therapy may improve survival. Elhassadi E; Flavin R; Browne P; Conneally E; Hayden P; Quinn F; Higgins E; Vandenberghe E Ir J Med Sci; 2017 Aug; 186(3):589-595. PubMed ID: 28321641 [TBL] [Abstract][Full Text] [Related]
9. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646 [TBL] [Abstract][Full Text] [Related]
10. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097 [TBL] [Abstract][Full Text] [Related]
11. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A; Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647 [TBL] [Abstract][Full Text] [Related]
12. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab. Berinstein NL; Bhella S; Pennell NM; Cheung MC; Imrie KR; Spaner DE; Milliken V; Zhang L; Hewitt K; Boudreau A; Reis MD; Chesney A; Good D; Ghorab Z; Hicks LK; Piliotis E; Buckstein R Ann Hematol; 2015 May; 94(5):813-23. PubMed ID: 25567231 [TBL] [Abstract][Full Text] [Related]
13. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with Uryu H; Mishima Y; Tsuyama N; Yokoyama M; Nishimura N; Fukuta T; Shirouchi Y; Okabe T; Inoue N; Takeuchi K; Terui Y Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498 [TBL] [Abstract][Full Text] [Related]
14. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991 [TBL] [Abstract][Full Text] [Related]
15. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma. Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285 [TBL] [Abstract][Full Text] [Related]
16. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600 [TBL] [Abstract][Full Text] [Related]
17. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654 [TBL] [Abstract][Full Text] [Related]
18. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707 [TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study. Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD; Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]